An update on the status of endothelin receptor antagonists for hypertension

Expert Opinion on Investigational Drugs

Volumn 10, Issue 11, 2001, Pages 1937-1946

  Dao, H H ^a   Moreau, P ^a  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

Combination therapy; End organ damage; Endothelin; Endothelin receptor antagonists; Hypertension; Hypertrophy; Vascular remodelling

Indexed keywords

ANGIOTENSIN; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BOSENTAN; CALCIUM CHANNEL BLOCKING AGENT; DARUSENTAN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; ENDOTHELIN RECEPTOR ANTAGONIST; LOSARTAN; PLACEBO; TAK 044;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIHYPERTENSIVE ACTIVITY; ARTERIAL PRESSURE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG INDICATION; DRUG INDUSTRY; DRUG MARKETING; DRUG MECHANISM; DRUG POTENTIATION; DRUG SYNTHESIS; HEADACHE; HEART FAILURE; HUMAN; HYPERTENSION; LIVER TOXICITY; MOUSE; NONHUMAN; PROTECTION; PULMONARY HYPERTENSION; RAT; REVIEW; STROKE; TISSUE INJURY;

ANIMALS; ANTIHYPERTENSIVE AGENTS; DRUG THERAPY, COMBINATION; ENDOTHELINS; HUMANS; HYPERTENSION; RECEPTORS, ENDOTHELIN;

EID: 0035158807     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.10.11.1937     Document Type: Review

References (89)

1. Endothelin receptor antagonists: Novel agents for the treatment of hypertension
2. Endothelins and endothelin receptor antagonists: Therapeutic considerations for a novel class of cardiovascular drugs
3. The therapeutic potential of endothelin receptor antagonists in cardiovascular disease
4. A novel potent vasoconstrictor peptide produced by vascular endothelial cells
5. XXX: ECE-1: A membrane-bound metalloprotease that catalyses the proteolytic activation of big endothelin-1
6. Cloning and functional expression of endothelin-converting enzyme from rat endothelial cells
7. Polar secretion of endothelin-1 by cultured endothelial cells
8. Endothelin-1 and endothelin-3 release EDRF from isolated perfused arterial vessels of the rat and rabbit
9. B receptors mediate contraction to endothelin-1 in human blood vessels
10. Endothelin blockers and renal protection: A new strategy to prevent end-organ damage in CV diseases?
11. Vascular biology of endothelin
12. Pathophysiology of endothelin in the cardiovascular system
13. Endothelin stimulated by angiotensin II augments contractility of spontaneously hypertensive rat resistance arteries
14. Mitogens for adult rat aortic vascular smooth muscle cells in serum-free primary culture
15. Endothelin stimulates protein systhesis in smooth muscle cells
16. ET-1 cooperates with EGF to induce mitogenesis via a PTX-sensitive pathway in airway smooth muscle cells
17. Apoptosis in aorta of deoxycorticosterone acetate-salt hypertensive rats: Effect of endothelin receptor antagonism
18. Endothelin-1 as an autocrine/paracrine apoptosis survival factor for endothelial cells
19. Vascular endothelin-1 gene expression and synthesis and effects on renal Type I collagen synthesis and nephroangiosclerosis during nitric oxide synthase inhibition in rats
20. Endothelin system-dependent cardiac remodelling in renovascular hypertension
21. Extracellular matrix contraction by fibroblasts: Peptide promoters and second messengers
22. Endothelin-1 transgenic mice develop glomerulosclerosis, interstitial fibrosis, and renal cysts but not hypertension
23. Characterisation of the renal phenotype of transgenic rats expressing the human endothelin-2 gene
24. Vascular hypertrophy and remodelling in secondary hypertension
25. Cellular hypertrophy in subcutaneous small arteries of patients with renovascular hypertension
26. Urinary and plasma endothelin-1 in essential hypertension and in hypertension secondary to renoparenchymal disease
27. Increased plasma endothelin concentration in atherosclerotic renovascular hypertension
28. Small artery structure in hypertension: Dual process of remodelling and growth
29. Enhanced expression of endothelin-1 gene in resistance arteries in severe human essential hypertension
30. ET(A) receptor antagonist prevents blood pressure elevation and vascular remodelling in aldosterone-infused rats
31. Transient involvement of endothelin in hypertrophic remodelling of small arteries
32. A-receptor antagonist
33. Cardiac and vascular hypertrophy in hypertension due to angiotensin II. Effect of losartan and bosentan
34. Norepineprhine-induced aortic hyperplasia and extracellular matrix deposition is endothelin-dependent
35. A receptor blockade attenuates cardiac hypertrophy independently of blood pressure effects in renovascular hypertensive rats
36. Effect of endothelin antagonism on blood pressure and vascular structure in renovascular hypertensive rats
37. Modulation of cardiac natriuretic peptide gene expression following endothelin type A receptor blockade in renovascular hypertension
38. A-selective endothelin receptor antagonism on blood pressure in experimental and genetic hypertension in rats
39. Effect of chronic treatment of adult spontaneously hypertensive rats with an endothelin receptor antagonist
40. Endothelin antagonism in end-organ damage of spontaneously hypertensive rats. Comparison with angiotensin-converting enzyme inhibition and calcium antagonism
41. Early, but not late-onset, endothelin A receptor blockade can modulate hypertension, cerebral oedema and proteinuria in stroke-prone hypertensive rats
42. Prolonged endothelin blockade prevents hypertension and cardiac hypertrophy in stroke-prone spontaneously hypertensive rats
43. Effects of endothelin receptor inhibition on cerebral arterioles in hypertensive rats
44. Marked reduction of mortality in salt-loaded Dahl salt-sensitive rats by the new, selective endothelin ETA receptor antagonist, J-105859
45. Endothelin-A-receptor blockade improves renal function and doubles the lifespan of stroke-prone spontaneously hypertensive rats
46. Cardiovascular effects of endothelin-1 and endothelin antagonists in conscious, hypertensive ((mRen-2)27) rats
47. Blockade of angiotensin II Type 1 receptor and not of endothelin receptor prevents hypertension and cardiovascular disease in transgenic (mREN2)27 rats via adrenocortical steroid-independent mechanisms
48. The vasoconstriction induced by endothelin-1 is mediated only by ET(A) receptors in mesenteric small resistance arteries of spontaneously hypertensive rats and Wistar Kyoto rats
49. Elevation of blood pressure by genetic and pharmacological disruption of the ETB receptor in mice
50. Salt-sensitive hypertension in endothelin-B receptor-deficient rats
51. Exaggerated vascular and renal pathology in endothelin-B receptor-deficient rats with deoxycorticosterone acetate-salt hypertension
52. The role of ETB receptors in normotensive and hypertensive rats as revealed by the non-peptide selective ETB receptor antagonist Ro 46-8443
53. Evidence for endothelin involvement in the response to high salt
54. The effect of an endothelin receptor antagonist, bosentan, on blood pressure in patients with essential hypertension
55. Selective ET(A) receptor antagonism with ABT-627 attenuates all renal effects of endothelin in humans
56. Pharmacokinetics and pharmacodynamic effects of ABT-627, an oral ETA selective endothelin antagonist, in humans
57. Pharmacokinetics and pharmacodynamics of the endothelin receptor antagonist bosentan in healthy human subjects
58. Systemic endothelin receptor blockade decreases peripheral vascular resistance and blood pressure in humans
59. The increase in human plasma immunoreactive endothelin but not big endothelin-1 or its C-terminal fragment induced by systemic administration of the endothelin antagonist TAK-044
60. Vasoconstriction to endogenous endothelin-1 is increased in the peripheral circulation of patients with essential hypertension
61. LU135252: An endothelin A receptor antagonist for treatment of hypertension, dose response, efficacy and safety. The HEAT study: Hypertension, Endothelin Antagonist Treatment
62. Endothelin-A receptor antagonist-mediated vasodilatation is attenuated by inhibition of nitric oxide synthesis and by endothelin-B receptor blockade
63. Systemic blockade of the endothelin-B receptor increases peripheral vascular resistance in healthy men
64. Bosentan in essential hypertension
65. Role of endothelin in the increased vascular tone of patients with essential hypertension
66. The endothelin antagonist bosentan inhibits the canalicular bile salt export pump: A potential mechanism for hepatic adverse reactions
67. Effects of long-term selective ETA receptor blockade on neurohumoral activation in congestive heart failure
68. Cranial and cardiac neural crest defects in endothelin-A receptor-deficient mice
69. Cardiac endothelin system impairs left ventricular function in renin- dependent hypertension via decreased sarcoplasmic reticulum Ca(2+) uptake
70. Endothelin-A receptor antagonist inhibits angiotensin II and noradrenaline in man
71. Synergistic effects of AT(1) and ET(A) receptor blockade in a transgenic, angiotensin II-dependent, rat model
72. Endothelin and its antagonists in hypertension: Can we foresee the future?
73. Racial differences in plasma endothelin-1 concentrations in individuals with essential hypertension
74. Salt intake and hypertensive renal injury in African Americans
75. The heterogeneity of hypertension: Why doesn't every patient respond to every antihypertensive drug?
76. Actual blood pressure control: Are we doing things right?
77. Effects of nonpeptide endothelin receptor antagonists in rats with reduced renal mass
78. Blood pressure and vascular effects of endothelin blockade in chronic nitric oxide-deficient hypertension
79. Effect of a nonselective endothelin antagonist on vascular remodelling in deoxycorticosterone acetate-salt hypertensive rats: Evidence for a role of endothelin in vascular hypertrophy
80. Respective role of humoral factors and blood pressure in cardiac remodelling of DOCA hypertensive rats
81. Combined effects of AT(1) and ET(A) receptor antagonists, candesartan, and A-127722 in DOCA-salt hypertensive rats
82. Different contributions of endothelin-A and endothelin-B receptors in the pathogenesis of deoxycorticosterone acetate-salt-induced hypertension in rats
83. Prevention of the cardiovascular and renal effects of angiotensin II by endothelin blockade
84. Vascular endothelin-1 expression and effect of an endothelin ETA antagonist on structure and function of small arteries from stroke- prone spontaneously hypertensive rats
85. A-receptor blockade
86. Endothelin-A receptor antagonism attenuates the hypertension and renal injury in Dahl salt-sensitive rats
87. A-receptor blockade prevents increased tissue endothelin-1, vascular hypertrophy, and endothelial dysfunction in salt-sensitive hypertension
88. A endothelin receptor antagonism after nitric oxide synthase inhibition with L-NAME in normal rats
89. Effect of endothelin blockade on pressure natriuresis in nitric oxide-deficient hypertensive rats